MAD2L2 (mitotic arrest deficient 2 like 2)

2003-02-01  

Identity

HGNC
LOCATION
1p36.22
LOCUSID
ALIAS
FANCV,MAD2B,POLZ2,REV7
FUSION GENES

Other Information

Locus ID:

NCBI: 10459
MIM: 604094
HGNC: 6764
Ensembl: ENSG00000116670

Variants:

dbSNP: 10459
ClinVar: 10459
TCGA: ENSG00000116670
COSMIC: MAD2L2

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000116670ENST00000235310Q9UI95
ENSG00000116670ENST00000235310A0A024R4I4
ENSG00000116670ENST00000376667Q9UI95
ENSG00000116670ENST00000376667A0A024R4I4
ENSG00000116670ENST00000376669B1AK44
ENSG00000116670ENST00000376672B1AK44
ENSG00000116670ENST00000376692Q9UI95
ENSG00000116670ENST00000376692A0A024R4I4
ENSG00000116670ENST00000445656B1AK43
ENSG00000116670ENST00000456915B1AK45

Expression (GTEx)

0
10
20
30
40
50
60
70

Pathways

PathwaySourceExternal ID
Cell cycleKEGGko04110
Progesterone-mediated oocyte maturationKEGGko04914
Cell cycleKEGGhsa04110
ShigellosisKEGGhsa05131
Progesterone-mediated oocyte maturationKEGGhsa04914
Oocyte meiosisKEGGko04114
Oocyte meiosisKEGGhsa04114
Bacterial invasion of epithelial cellsKEGGko05100
Bacterial invasion of epithelial cellsKEGGhsa05100
DNA polymerase zeta complexKEGGhsa_M00293
DNA polymerase zeta complexKEGGM00293
DNA RepairREACTOMER-HSA-73894
DNA Damage BypassREACTOMER-HSA-73893
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA templateREACTOMER-HSA-110313
Translesion synthesis by REV1REACTOMER-HSA-110312
Translesion synthesis by POLKREACTOMER-HSA-5655862
Translesion synthesis by POLIREACTOMER-HSA-5656121

Protein levels (Protein atlas)

Not detected
Low
Medium
High

References

Pubmed IDYearTitleCitations
381676492024MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.1
385151122024AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.0
385574432024REV7-p53 interaction inhibits ATM-mediated DNA damage signaling.0
381676492024MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.1
385151122024AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.0
385574432024REV7-p53 interaction inhibits ATM-mediated DNA damage signaling.0
365929302023Evolution of Rev7 interactions in eukaryotic TLS DNA polymerase Polζ.3
370476772023Bridging Gaps in HDR Improvement: The Role of MAD2L2, SCAI, and SCR7.2
370944312023Identification of the promoter region regulating the transcription of the REV7 gene.0
380175382023The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma.2
365929302023Evolution of Rev7 interactions in eukaryotic TLS DNA polymerase Polζ.3
370476772023Bridging Gaps in HDR Improvement: The Role of MAD2L2, SCAI, and SCR7.2
370944312023Identification of the promoter region regulating the transcription of the REV7 gene.0
380175382023The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma.2
360448442022CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair.7

Citation

Dessen P

MAD2L2 (mitotic arrest deficient 2 like 2)

Atlas Genet Cytogenet Oncol Haematol. 2003-02-01

Online version: http://atlasgeneticsoncology.org/gene/333/tumors-explorer/haematological-explorer/js/template.js